BioSpace News Archive

CCT Research, a leader in community-based, embedded clinical research, today announced the expansion of its clinical trial operations to the Salt Lake City metropolitan area.

Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that Dr. Darrin M. Beaupre will join the company as its Chief Medical Officer, Oncology.

Combination of free user-friendly web tool, to obtain custom probe sequences, and enzyme-based technology allows for efficient depletion of abundant RNAs for virtually any organism and sample type.

EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these «super» biological nanoparticles, the exosomes.

Bayer and Blackford Analysis have entered into a development and license agreement to establish an artificial intelligence (AI) platform for medical imaging. This agreement supports Bayer’s commitment to expanding its AI capabilities and accelerating innovation in radiology

DECN Announces Significant Agreement With Russian Federation Partner for Genviro! and Genviro! Pro COVID-19 Testing Kits as Well as Its Venerable GenUltimate! Blood Glucose Products

Rafarma Pharmaceuticals, Inc.OTC:(RAFA) has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia (https://vaccineslab.com/).

Novartis today announced that the US Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids

– Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation – – Xolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma –

Rising Biosciences, Inc. (OTC PINK:RBII) CEO Arthur Hall reported that the company is expecting to achieve and surpass a milestone sales benchmark in the fiscal year 2020.